1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3) is sponsored by National Institute on Drug Abuse. Supports high-impact research on the discovery and development of medications, devices, and digital therapeutics to prevent and treat substance use disorders and overdose.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute on Drug Abuse” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Key questions and narrative sections extracted from the solicitation.
Research strategy and specific aims
Milestone definitions with quantifiable metrics for UG3 phase
Go/no-go decision criteria for UG3 to UH3 transition
Study timeline and FDA pathway entry/exit points
Resource sharing and data management plan
Scoring criteria used to review proposals for this grant.
According to the current listing, eligibility includes: Universities, nonprofits, small businesses, and state/local governments. Confirm the full requirements in the official notice before applying.
The published deadline was February 26, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3) is funded by National Institute on Drug Abuse. Verify program details on the funder's official page before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The solicitation lists 6 required documents: Research strategy with study timeline, Decision tree with go/no-go decision points, FDA development entry/exit points, UG3 success metrics and milestone descriptions, Data Management and Sharing Plan, and IDE documentation or exemption justification (device studies). Check the official notice for formatting and page-limit rules.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.